Announcements Trials
Browse Landscape

Phase

Phase 2 80Phase 3 47Phase 1/2 23Phase 1 22Phase 2/3 4Phase EARLY_PHASE1 3Phase 4 3Phase NA 1

Status

Completed 5Active not recruiting 3Withdrawn 2Recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1

Conditions

Neurotoxicity Syndromes 1Multiple Myeloma 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

pembrolizumab 8Nivolumab 7Magnetic Resonance Spectroscopy 7Radiotherapy 6Biopsy 4Temozolomide 3Specimen Handling 3Irinotecan 3Ipilimumab 3Fluorodeoxyglucose F18 3Dexamethasone 3Bevacizumab 3venetoclax 2niraparib 2gallium 68 PSMA-11 2durvalumab 2avelumab 2Tobacco Use Cessation Devices 2Standard of Care 2Rituximab 2Positron-Emission Tomography 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2Neoadjuvant Therapy 2Metastasectomy 2Immunoglobulin G 2FAPI-46 2Disulfides 2Cyclophosphamide 2Cetuximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Active not recruiting × Dexamethasone × Clear all
NCT04161248 2026-05-12

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Canadian Cancer Trials Group

Phase EARLY_PHASE1 Active not recruiting
40 enrolled
Lymphoid

Lymphoma, B-Cell

NCT04514029 2026-01-08

Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel

Masonic Cancer Center, University of Minnesota

Phase EARLY_PHASE1 Active not recruiting
37 enrolled
Lymphoid

Lymphoma, Neurotoxicity Syndromes

NCT05560399 2026-01-02

CC-220

Icahn School of Medicine at Mount Sinai

Phase EARLY_PHASE1 Active not recruiting
7 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡